The FDA has approved Olumiant, the first systemic medication for the treatment of alopecia areata, according to a press release.
Olumiant (baricitinib, Eli Lilly/Incyte) is a once-daily oral Janus kinase (JAK) inhibitor that has previously been approved for rheumatoid arthritis and atopic dermatitis.
“There is a significant unmet medical need for people with alopecia areata given there has never been an FDA-approved medicine,» Patrik Jonsson, Lilly senior vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, said in a statement to Healio. «Our